A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Kristin A Altwegg,Suryavathi Viswanadhapalli,Monica Mann,Dimple Chakravarty,Samaya Krishnan,Zexuan Liu,Junhao Liu,Uday P Pratap,Behnam Ebrahimi, John R Sanchez,Xiaonan Li,Shihong Ma,Ben H Park,Bindu Santhamma,Yidong Chen,Zhao Lai,Ganesh V Raj,Yaxia Yuan,Daohong Zhou,Gangadhara R Sareddy,Rajeshwar R Tekmal,Stan McHardy,Tim H-M Huang,Manjeet K Rao,Hariprasad Vankayalapati,Ratna K Vadlamudi Cancer research（2022）
摘要
Development of a novel inhibitor of oncogenic PELP1 provides potential therapeutic avenues for treating therapy-resistant, advanced ER+ breast cancer.
更多查看译文
AI 理解论文
溯源树
样例
